The objective of this study is to find out what the pharmacodynamic (PD) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children). The main questions the investigators want to answer are: * Are differences related to the pathophysiological factors involved in nocturia? * Are there age/gender/size differences? * Can the investigators identify patients who are likely to develop hyponatraemia? * Can the investigators individualize treatment and reduce risk for hyponatraemia? The patient will be given a prescription to buy Minirin Melt 60µg at the local pharmacy. During 30 days, the patient has to take Minirin Melt 60µg in the evening before going to bed. There are two groups of patients: Group A: Patients that still have to undergo an evaluation phase, according to standard procedures (e.g. osmolality test, blood sample). This procedure is not a part of this study. The study starts when the 1st Minirin Melt tablet has been taken (= day 1). Group B: This group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed Minirin Melt 60 µg ambulatory. The study starts when the patients takes his first prescribed Minirin Melt tablet: * On day 3 and day 7 a blood sample will be taken at the UZ Ghent for safety control (Na+, K+, creatinin, osmolality = good clinical practice guideline). These first 2 visits (day 3 and day 7) are standard procedure. If the patient is at high risk for side effects, blood has to be taken during the first 7 days. * On day 3 the patient has to give a urine sample. * Patients have to fill out a frequency/volume chart during the first 14 days. * On day 30, a 3rd blood sample will be taken
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 3.
Timeframe: At day 3 after first desmopressin intake.
Urine sample for urine concentration of Na+, K+, creatinin and osmolality
Timeframe: At day 3
Area Under Curve (AUC) frequency/volume chart during the first 14 days
Timeframe: Every day during the first 14 days.
The decrease of number of nocturnal micturition episodes.
Timeframe: At day 0
The decrease of the number of nocturnal micturition episodes.
Timeframe: At day 30
Registration of number of side effects at day 3.
Timeframe: At day 3
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 7.
Timeframe: At day 7 after first desmopressin intake
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 30.
Timeframe: At day 30 after first desmopressin intake
Registration of number of side effects at day 7
Timeframe: At day 7
Registration of number of side effects at day 30.
Timeframe: At day 30